Clinical Trial: Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine

U.S., May 17 -- ClinicalTrials.gov registry received information related to the study (NCT06974617) titled 'Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine' on May 08.

Brief Summary: This trial compares the efficacy and safety of sphenopalatine ganglion block (SPGB) and intramuscular BOTOX injection in chronic migraine.

Study Start Date: May 15

Study Type: INTERVENTIONAL

Condition: Sphenopalatine Block BOTOX Chronic Migraine

Intervention: DRUG: Sphenopalatine block

Patients will receive 2 ml of 2% lidocaine using a nasal applicator in each nostril.

DRUG: Botulinum Toxin Type A

Patients will receive Botulinum Toxin Type A 100 units administered in a fixed dose and site paradigm.

Recruitment Status: RECRUITING ...